The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change
- 27 November 2017
- Vol. 73 (3), 705-712
- https://doi.org/10.1111/all.13345
Abstract
Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated whether response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels. Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with omalizumab 300 mg/4 weeks for 12 weeks, when their treatment responses, that is, no, partial, or complete response, were assessed by use of the urticaria activity score, physician and patient visual analog scale, and treatment effectiveness score. Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE). Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032). Nonresponders also had lower w4IgE levels and lower ratios of w4IgE/bIgE levels than partial and complete responders (P < .001). Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016). In CSU, total IgE levels and their change predict the response to treatment with omalizumab. The assessment of pre- and post-treatment IgE levels and their ratio may help to improve the management of CSU in patients who require omalizumab treatment.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- Omalizumab is effective in nonautoimmune urticariaJournal of Allergy and Clinical Immunology, 2011
- Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double‐blind, placebo‐controlled studyClinical and Experimental Allergy, 2004
- Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patientsAllergy, 2004
- The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test resultsJournal of Allergy and Clinical Immunology, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- The relationship between serum IgE and surface levels of FcϵR on human leukocytes in various diseases: Correlation of expression with FcϵRI on basophils but not on monocytes or eosinophilsJournal of Allergy and Clinical Immunology, 2000
- Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcϵRI or anti-IgE autoantibodiesJournal of the American Academy of Dermatology, 1999
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitisJournal of Allergy and Clinical Immunology, 1997
- The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.JCI Insight, 1997